Rare diseases and orphan drugs
Clinically relevant drug interactions with antiepileptic drugs
Disposition and pharmacodynamics of propofol during isovolaemic haemorrhage followed by crystalloid resuscitation in humans
Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy
Pharmacokinetics of a new testosterone transdermal delivery system, TDS®-testosterone in healthy males
Tadalafil pharmacokinetics in healthy subjects
Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone
Genetic polymorphisms in KCNQ1, HERG, KCNE1 and KCNE2 genes in the Chinese, Malay and Indian populations of Singapore
Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status
Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes
The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia
Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids
Low incidence of hypertensive disorders of pregnancy in women treated with spiramycin for toxoplasma infection
When gatekeepers meet the sentinel : the impact of a prior authorization requirement for cefuroxime on the prescribing behaviour of community-based physicians
Curriculum development in pharmacotherapy : testing the ability of preclinical medical students to learn therapeutic problem solving in a randomized controlled trial
Initial phase of chronic medication use: patients' reasons for discontinuation
Orphan drug development is progressing too slowly
Hydroxylation of lansoprazole in poor metabolizers of CYP2C19
Hydroxylation of lansoprazole in poor metabolizers of CYP2C19
ASCOT – old or new drugs for blood pressure?